Fig. 1 · Structure

Documents & Downloads

Isradipine

Cat. No. A10487 CAS 75695-93-1

calcium channel blocker

Isradipine is a calcium channel blocker of the dihydropyridine class.

In Stock

Publications for Isradipine

1 publication citing this product

  1. Deborah A. Goldspink, .et al. , Mol Metab, 2018, Jan; 7: 90-101 PMID: 29167062

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Isradipine inhibits L-type CaV1.2 and CaV1.3 calcium currents with potency that depends on channel isoform, splice variant and electrical activity. In HEK293 cells under dopamine-neuron-like pacemaking, reported IC50 values were 2.9 nM for CaV1.2, 6.9 nM for long CaV1.3 and 16.8 nM for short CaV1.3. CaV1.2 under arterial smooth-muscle-like activity had an IC50 of 1.5 nM. These current-inhibition results do not establish CaV1.3 selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Calcium channel

In Vitro Studies

In murine ileal organoid-derived L-cells, acute 10 µM isradipine inhibited a smaller calcium-current component than P/Q-type channel blockade and had little effect on action-potential peak. The calcium-current experiment used sequential blockers, so its result describes pharmacological partitioning of current. [2]

Isradipine-sensitive currents in murine ileal organoid L-cells

Cell-based study · Identified murine ileal organoid-derived L-cells in 2D culture; perforated-patch electrophysiology at 20–24 °C [2]

Acute 10 µM isradipine had little effect on the action-potential peak. In isolated calcium-current recordings, isradipine inhibited a smaller component than the preceding P/Q-type blocker; cadmium blocked remaining current.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Action-potential peak inhibition relative to total block with TTX plus cadmiumQualitative effect Little effect at 10 µM[2]
Relative contributions of calcium-channel subtypes to isolated calcium currentQualitative pharmacological partition P/Q-type component predominated; smaller isradipine-sensitive L-type component[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
Acute perfusion during recording; exposure time not specified
Method
Direct gravity-fed perfusion; organoids plated 1–3 days before recording
Co-treatment
Calcium-current partition used sequential channel blockers; this is not an isradipine-alone total-current effect.
Reported limits
Stock solvent, isradipine lot/catalog identifier, exact exposure time and numerical effect sizes are not supplied in the selected experiment text.
Methods and source locations

Compound reported in the paper: Isradipine; Compound label in the paper: isradipine

Applies to the named isradipine tested in this model. No salt conversion, stereoisomer equivalence or validation of the current Adooq lot is inferred.

Results 3.2; Figure 2Cv and Fi–iii; Methods 2.6, 2.8–2.9

Action-potential peak inhibition relative to total block with TTX plus cadmium: Current clamp; peak normalized to total block with 0.3 µM TTX + 100 µM Cd2+; Figure 2Cv uses mean ± SEM with individual cells. — Figure 2Cv; Results 3.2; Methods 2.6

Relative contributions of calcium-channel subtypes to isolated calcium current: Perforated-patch voltage clamp with 0.3 µM TTX; sequential 0.5 µM ω-agatoxin-IVA, 10 µM isradipine and 100 µM cadmium; shown responses at +10 mV from −80 mV. — Figure 2Fi–iii; Results 3.2; Methods 2.6 and 2.8

Activity-dependent inhibition of human CaV1.2 and CaV1.3 channels

Cell-based study · HEK293 cells expressing human CaV1.2, long CaV1.3 or short CaV1.3 (42A) with β3/α2δ1; whole-cell current recordings in 2 mM extracellular Ca2+ at approximately 22 °C [1]

Isradipine inhibited all three channel constructs with activity- and isoform-dependent potency. During simulated SN dopamine-neuron pacemaking, CaV1.3 was less sensitive than CaV1.2. CaV1.2 under arterial smooth-muscle-like activity was the most sensitive condition compared.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Steady-state calcium-current inhibition, human CaV1.2, SN DA-like pacemakingIC50, mean (95% CI) 2.9 nM (2.2–3.9 nM)[1]
Steady-state calcium-current inhibition, human CaV1.3 long, SN DA-like pacemakingIC50, mean (95% CI) 6.9 nM (5.8–8.3 nM)[1]
Steady-state calcium-current inhibition, human CaV1.3 short, SN DA-like pacemakingIC50, mean (95% CI) 16.8 nM (14.1–19.9 nM)[1]
Steady-state calcium-current inhibition, human CaV1.2, aSM-like activityIC50, mean (95% CI) 1.5 nM (1.2–1.7 nM)[1]

Literature-Reported Treatment Conditions

Treatment concentration
1–50 nM for SN DA-like recordings; 0.3–10 nM for aSM-like recordings; 3 µM for complete block
Exposure duration
Applied after steady-state current was reached; no single common exposure duration stated
Method
Whole-cell patch clamp; one test concentration per cell
Vehicle
DMSO; maximum final concentration 0.1% v/v
Co-treatment
No combination drug efficacy experiment; 3 µM ISR served as the full-block control
Reported limits
Per-concentration n varies in the figure; no total n or fixed exposure duration is inferred.
Methods and source locations

Compound reported in the paper: Isradipine; Compound label in the paper: ISR

Applies to the named isradipine tested in this model. No salt conversion, stereoisomer equivalence or validation of the current Adooq lot is inferred.

Results ISR sensitivity; Figures 4A–C and 5A–B; Methods whole-cell recordings, aSM/SN DA protocols and Drug perfusion

Steady-state calcium-current inhibition, human CaV1.2, SN DA-like pacemaking: 2.5 Hz SN DA-like voltage waveform; peak action-potential current; rundown corrected using vehicle controls; residual current subtracted after 3 µM ISR. — Results ISR sensitivity; Figure 5B; Figure 4 controls

Steady-state calcium-current inhibition, human CaV1.3 long, SN DA-like pacemaking: Same concentration-response design and controls as Figure 4; each cell received a single test ISR concentration followed by full block. — Results ISR sensitivity; Figure 5B

Steady-state calcium-current inhibition, human CaV1.3 short, SN DA-like pacemaking: Same concentration-response design and controls as Figure 4. — Results ISR sensitivity; Figure 5B

Steady-state calcium-current inhibition, human CaV1.2, aSM-like activity: Voltage ramps between −57 and −25 mV at 32 mV/s, sweep interval 8 s; vehicle rundown correction and 3 µM ISR full-block subtraction. — Results aSM comparison; Figure 5A–B; Methods aSM tone protocol

In Vivo Studies

In one male-mouse 6-OHDA lesion study, systemic isradipine pretreatment did not rescue substantia nigra TH-positive dopamine-neuron loss versus placebo in the analyzed cohort with terminal plasma concentrations ≥3 ng/ml. This negative result is specific to the tested model and exposure conditions. [1]

In a separate juvenile-mouse study, systemic isradipine for 7–10 days reduced dendritic calcium oscillations measured ex vivo without a discernible change in autonomous dopamine-neuron pacemaking. Calcium oscillations returned to control levels 5–7 days after pump removal. These findings demonstrate a physiological response under those conditions; they do not establish neuronal survival benefit. [3]

No neuroprotection in the tested mouse lesion model

Animal study · Male C57BL/6 wild-type mice, 12–15 weeks old; unilateral 6-OHDA nigrostriatal lesion model [1]

In the analyzed cohort with terminal plasma ISR concentrations ≥3 ng/ml, systemic pretreatment did not rescue TH+ SN dopamine-neuron loss compared with placebo.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TH+ substantia nigra dopamine neurons remaining on lesioned side relative to nonlesioned side, 28 days after lesionQualitative treatment comparison No neuroprotection detected; ISR n = 18, placebo n = 28; four independent experiments[1]

Conditions shared by the study groups

Route
Pellet implantation or subcutaneous osmotic minipumps
Frequency
Sustained-release administration
Treatment course
Started 7 days before lesion; TH+ neuronal survival assessed 28 days after lesion
Vehicle
Minipump vehicle: DMSO/PEG300; pellet carrier composition not specified in selected text
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pooled systemic isradipine treatment
Extended-release pellets 6 or 9 mg/kg/d; or osmotic minipumps 3 mg/kg/d
Placebo-treated wild-type mice; lesion-side neuronal counts normalized to nonlesioned sideNo rescue of TH+ SN dopamine-neuron loss; ISR n = 18 versus placebo n = 28 for the lesioned-side comparison[1]
Pooled systemic isradipine treatment
Model: Male C57BL/6 wild-type mice, 12–15 weeks old; unilateral 6-OHDA nigrostriatal lesion model
Reported limits: Outcomes are pooled across delivery regimens; no dose-specific efficacy inferred. Continuous pump delivery through the full assessment period is not independently established in the selected text.
Methods and source locations

Compound reported in the paper: Isradipine; Compound label in the paper: ISR

Applies to the named isradipine tested in this model. No salt conversion, stereoisomer equivalence or validation of the current Adooq lot is inferred.

Results first subsection; Figure 1B,D,E; Methods Animals, Isradipine treatment and plasma concentration measurement

TH+ substantia nigra dopamine neurons remaining on lesioned side relative to nonlesioned side, 28 days after lesion: Stereological TH+ neuronal counts; approximately 50% neuronal loss reported in Results; no exact survival percentage inferred from bars. — Results first subsection; Figure 1B,D and caption

Pooled systemic isradipine treatment · Results first subsection; Figure 1B,D,E; Methods Animals, Isradipine treatment and plasma concentration measurement

Chronic systemic isradipine reduces dendritic calcium signals

Animal study · Juvenile male mouse SNc dopamine neurons after systemic dosing; ex vivo brain-slice dendritic calcium imaging and pacemaking recordings [3]

After 7–10 days of systemic isradipine, dendritic calcium oscillations were reduced without a discernible pacemaking-rate change. Calcium oscillations returned to control levels 5–7 days after pump removal.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Peak and average proximal and distal dendritic calcium during SNc neuronal pacemakingQualitative decrease; P < 0.05 Lower after chronic isradipine; proximal: control 28 neurons/23 mice, ISR 5 neurons/5 mice; distal: control 31 neurons/22 mice, ISR 8 neurons/8 mice[3]
Autonomous SNc dopamine-neuron spike rate after chronic treatmentNo discernible change Vehicle: 9 neurons from 4 mice; isradipine: 11 neurons from 4 mice[3]
Dendritic calcium oscillations after removal of the isradipine pumpReversibility Returned to control levels 5–7 days after pump removal; 5 neurons from 5 mice for each dendritic location[3]

Conditions shared by the study groups

Route
Subcutaneous osmotic minipumps
Frequency
Continuous delivery
Treatment course
7–10 days
Vehicle
50% DMSO/15% PEG300/double-distilled water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Chronic systemic isradipine
3 µg/g/d
Control dendritic measurements from Figure 2B–C; pacemaking comparison against vehicle-treated micePeak and average proximal/distal dendritic calcium decreased; pacemaking rate unchanged[3]
Chronic systemic isradipine
Model: Juvenile male mouse SNc dopamine neurons after systemic dosing; ex vivo brain-slice dendritic calcium imaging and pacemaking recordings
Reported limits: Control dendritic values are reused from Figure 2, not a separately randomized concurrent group stated for Figure 4. Salt, stereochemical composition and pump-drug supplier not established in the selected sections.
Methods and source locations

Compound reported in the paper: Isradipine; Compound label in the paper: isradipine

Applies to the named isradipine tested in this model. No salt conversion, stereoisomer equivalence or validation of the current Adooq lot is inferred.

Results chronic-treatment paragraphs around Figure 4; Figure 4B–F; Methods Chronic isradipine treatment, Animals and imaging

Peak and average proximal and distal dendritic calcium during SNc neuronal pacemaking: Whole-cell recording plus Fura-2 two-photon imaging; Figure 4E–F uses box plots; one-tailed Mann–Whitney U test with Dunn correction. Values not reconstructed from boxes. — Results chronic-treatment section; Figure 4D–F and caption; Methods imaging and Statistics

Autonomous SNc dopamine-neuron spike rate after chronic treatment: Perforated-patch recording; Figure 4B–C. — Figure 4B–C and caption; Results chronic-treatment section

Dendritic calcium oscillations after removal of the isradipine pump: Same calcium-imaging design; washout comparison in Figure 4E–F. — Figure 4D–F and caption; Results paragraph on removal of isradipine pumps; Methods Chronic isradipine treatment

Chronic systemic isradipine · Results chronic-treatment paragraphs around Figure 4; Figure 4B–F; Methods Chronic isradipine treatment, Animals and imaging

Specifications

Manufacturer Adooq Bioscience
Actions Blocker
CAS Number 75695-93-1
Applications calcium channel blocker
Formula C19H21N3O5
Molecular Weight 371.4
Synonyms DynaCirc; Prescal; PN-200-110; Clivoten; Esradin
SMILES
CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 71 mg/mL (191.17 mM)
Water Insoluble
Ethanol Warmed: 71 mg/mL (191.17 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Ortner NJ, Bock G, Dougalis A, et al. Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease. The Journal of neuroscience : the official journal of the Society for Neuroscience (2017). PMID: 28592699 DOI: 10.1523/jneurosci.2946-16.2017 Source material
  2. [2] Goldspink DA, Lu VB, Billing LJ, et al. Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 secreting cells. Molecular metabolism (2018). PMID: 29167062 DOI: 10.1016/j.molmet.2017.11.005 Source material
  3. [3] Guzman JN, Ilijic E, Yang B, et al. Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress. The Journal of clinical investigation (2018). PMID: 29708514 DOI: 10.1172/jci95898 Source material

Publications

1 publication citing this product

  1. Deborah A. Goldspink, .et al. , Mol Metab, 2018, Jan; 7: 90-101 PMID: 29167062

Added to your cart

View Cart Checkout
Loading...